超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究*

doi:10.3969/j.issn.1672-5069.2023.06.034

摘要/Abstract

摘要： 目的探讨应用超声造影(CEUS)肝脏影像报告与数据系统(LI-RADS)对乙型肝炎肝硬化患者肝内占位性病变性质的诊断价值。方法 2020年1月～2022年1月我院诊治的乙型肝炎肝硬化伴有肝内占位性病变患者521例,均进行肝穿刺病理学活检术和CEUS检查,应用LI-RADS对病灶进行分类诊断。应用MedCalc1 5.1统计学软件绘制受试者工作特征并计算曲线下面积(AUROC)判断LI-RADS的诊断效能。结果在521例存在肝内占位性病变的乙型肝炎肝硬化患者中,经病理学检查诊断HCC者96例,局灶性结节性增生(FNHL)150例,血管瘤162例,肝囊肿63例,局灶性脂肪肝50例;经CEUS检查和LI-RADS评估,发现I类病变248例(血管瘤145例,肝囊肿63例,局灶性脂肪肝40例),II类病变140例(均为FNHL),III类病变22例(FNHL者18例,HCC者4例),IV类病变39例(FNHL者6例,血管瘤7例,HCC 26例),V类病变72例(FNHL者6例,HCC 者66例);LI-RADS诊断V类病变的AUROC为0.84(95%CI:0.78～0.89),其灵敏度、特异度、阳性预测值和阴性预测值分别为68.8%、98.6%、91.7%和93.3%,显著优于对IV类病变【分别为0.62(95%CI:0.55～0.69)、27.1%、96.9%、66.7%和85.5%】或对III类病变【分别为0.50(95%CI:0.44～0.56)、4.2%、95.8%、18.2%和81.6%】的诊断(P＜0.05)。结论超声造影肝脏影像报告与数据系统诊断乙型肝炎肝硬化肝内I类、II类和V类病变的性质效能较高,而对于III类和IV类病变性质的诊断还需要综合考虑。

关键词: 肝细胞癌, 肝硬化, 超声造影, 肝脏影像报告与数据系统, 诊断

Abstract: Objective The aim of this study was to explore the diagnostic performance of contrast-enhanced ultrasound (CEUS) in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis (LC). Methods 521 patients with hepatitis B LC were admitted to our hospital between January 2020 and January 2022, and all underwent liver biopsy and CEUS. The intrahepatic space-occupying lesions were evaluated by liver imaging reporting and data system (LI-RADS).The diagnostic efficacy of LI-RADS was evaluated by the area under receiver operating characteristic curve (AUROC). Results Out of the 521 patients with LC in our series, the liver histopathological examination showed hepatocellular carcinoma (HCC) in 96 cases, focal nodular hyperplasia of liver (FNHL) in 150 cases, hepatic hemangioma (HH) in 162 cases, hepatic cysts in 63 cases and local fatty liver in 50 cases; the diagnosis of the LI-RADS based on the CEUS evaluation found type I lesions in 248 cases (HH in 145 cases, hepatic cysts in 63 cases and local fatty liver in 40 cases), type II lesions in 140 cases (all was FNHL), type III in 22 cases (FNHL in 18 cases and HCC in 4 cases), type IV lesions in 39 cases (FNHL in 6 cases, HH in 7 cases and HCC in 26 cases), and type V lesions in 72 cases (FNHL in 6 cases and HCC in 66 cases); the AUROC was 0.84(95%CI:0.78-0.89), with the sensitivity (Se), specificity (Sp), positive predicting value (PPV) and negative predicting value (NPV) of 68.8%, 98.6%, 91.7% and 93.3%, respectively, when the type V lesions was determined by LI-RADS, much superior to type IV lesions judged by LI-RADS [0.62(95%CI:0.55-0.69), 27.1%, 96.9%, 66.7% and 85.5%] or to type III lesions judged by LI-RADS [0.50(95%CI:0.44-0.56), 4.2%, 95.8%, 18.2% and 81.6%, P＜0.05]. Conclusion The diagnostic performance on type I, II and V intrahepatic lesions by liver imaging reporting and data system based on the contrast-enhanced ultrasound is excellent, but as for type III and IV lesions, the qualitative diagnosis might be difficult and should be made comprehensively.

Key words: Hepatocellular carcinoma, Liver cirrhosis, Contrast-enhanced ultrasound, Liver imaging reporting and data system, Diagnosis

周莉, 丁云清, 袁凤英, 陈竹, 冯志伟. 超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 903-906.

Zhou Li, Ding Yunqing, Yuan Fengying, et al. Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis[J]. Journal of Practical Hepatology, 2023, 26(6): 903-906.

参考文献

[1] Chidambaranathan-Reghupaty S, Fisher P B, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res,2021,149:1-61.
[2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中华消化外科杂志,2020,19(1):1-20.
[3] Galle P R, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int,2019,39(12):2214-2229.
[4] Ghosh S, Bhowmik S, Majumdar S, et al. The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein. Int J Cancer,2020,147(10):2934-2947.
[5] Chen L D, Ruan S M, Liang J Y, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: a predictive model using contrast-enhanced ultrasound. World J Gastroenterol,2018,24(33):3786-3798.
[6] Li J, Chen M, Wang Z J, et al. Interobserver agreement for contrast-enhanced ultrasound of liver imaging reporting and data system: a systematic review and meta-analysis. World J Clin Cases,2020,8(22):5589-5602.
[7] Fowler K J, Tang A, Santillan C, et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology,2018,286(1):173-185.
[8] Chernyak V, Flusberg M, Law A, et al. Liver imaging reporting and data system: discordance between computed tomography and gadoxetate-enhanced magnetic resonance imaging for detection of hepatocellular carcinoma major features. J Comput Assist Tomogr,2018,42(1):155-161.
[9] Williams EJ, Iredale JP, Williams EJ, et al. Liver cirrhosis. Postgrad Med J, 1998,74(870):193-202.
[10] Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol, 2016, 51(7):629-650.
[11] Fan Y, Li Y, Chu Y, et al. Toll-like receptors recognize intestinal microbes in liver cirrhosis. Front Immunol, 2021, 12:608498.
[12] Kono Y, Lyshchik A, Cosgrove D, et al. Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS(R)): the official version by the American college of radiology (ACR). Ultraschall Med,2017,38(1):85-86.
[13] Romanelli RG, Stasi C, Romanelli RG, et al. Recent advancements in diagnosis and therapy of liver dirrhosis. Curr Drug Targets, 2016, 17(15):1804-1817.
[14] 赵可馨,徐光文,李楠,等. 乙型肝炎病毒阳性肝硬化患者进展为肝细胞肝癌预测模型的建立及验证. 中华检验医学杂志,2022,45(5):516-521.
[15] Hoang J K, Middleton W D, Farjat A E, et al. Reduction in thyroid nodule biopsies and improved accuracy with American college of radiology thyroid imaging reporting and data system. Radiology,2018,287(1):185-193.
[16] Corwin M T, Lee A Y, Fananapazir G, et al. Nonstandardized terminology to describe focal liver lesions in patients at risk for hepatocellular carcinoma: implications regarding clinical communication. Am J Roentgenol,2018,210(1):85-90.
[17] 李芳,王衍森,翁璐昕. 高频超声肝实质纹理特征定量联合血清AFP-L3水平评估乙型肝炎肝硬化患者肝功能分级价值研究. 实用肝脏病杂志,2022,25(4):542-545.
[18] Chen L D, Ruan S M, Lin Y, et al. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS. Eur Radiol,2019,29(8):4249-4257.
[19] Furlan A. New progress toward validation of LI-RADS version 2018. Radiology,2019,291(1):81-82.
[20] Giorgio A, De Luca M, Gatti P, et al. CEUS LI-RADS categories to distinguish hepatocellular carcinoma and non-hepatocellular carcinoma malignancies. Radiology,2020,296(2):121-122.
[21] Cerny M, Bergeron C, Billiard J S, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology,2018,288(1):118-128.
[22] Schooler G R. American college of radiology LI-RADS in pediatric patients: the good, the bad, and the future. Pediatr Radiol,2019,49(6):707-709.
[23] Hartke J, Johnson M, Ghabril M, et al. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol, 2017,34(2):153-159.
[24] Dietrich C F, Potthoff A, Helmberger T, et al. Contrast-enhanced ultrasound: liver imaging reporting and data system (CEUS LI-RADS). Z Gastroenterol,2018,56(5):499-506.
[25] Sim HW, Knox J, Sim HW, et al. Hepatocellular carcinoma in the era of immunotherapy.Curr Probl Cancer, 2018,42(1):40-48.
[26] Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment.Curr Probl Diagn Radiol,2015,44(6):479-486.
[27] Lyshchik A, Kono Y, Dietrich C F, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY),2018,43(4):861-879.

超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*

Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	仲金龙, 施琳. miR-556-3p通过调控PTEN/AKT信号通路影响肝细胞癌的转移活性^*[J]. 实用肝脏病杂志, 2023, 26(6): 781-784.
[2]	邵孝如, 周筱, 葛颖颖. ¹⁸F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 811-814.
[3]	丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.
[4]	阎道博, 朱海超, 闪海霞. 瞬时弹性成像联合APRI诊断自身免疫性肝炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 831-834.
[5]	邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.
[6]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[7]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[8]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[9]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[10]	杨帆, 张小娟, 李丹, 姜莎莎, 张亮, 唐伟, 赵微. 胃镜下硬化术联合组织胶注射术治疗乙型肝炎肝硬化并发食管胃静脉曲张破裂出血患者1年再出血危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 875-878.
[11]	杨婉, 丁莉, 罗珂, 刘美. 肝细胞癌患者癌组织CK7和Glypican-3表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 883-886.
[12]	莫春明, 黄德佳, 韦惠章, 罗江伟. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 887-890.
[13]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[14]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[15]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.